| Autor: |
Wobma, Holly, Arvila, Sage R., Taylor, Maria L., Lam, Ki Pui, Ohashi, Marina, Gebhart, Catherine, Powers, Helene, Case, Siobhan, Chandler, Mia T., Chang, Margaret H., Cohen, Ezra, Day‐Lewis, Megan, Fishman, Martha P., Halyabar, Olha, Hausmann, Jonathan S., Hazen, Melissa M., Lee, Pui Y., Lo, Mindy S., Meidan, Esra, Roberts, Jordan E., Son, Mary Beth F., Sundel, Robert P., Dedeoğlu, Fatma, Nigrovic, Peter A., Casey, Alicia, Chang, Joyce, Henderson, Lauren A. |
| Zdroj: |
Arthritis Care and Research; October 2023, Vol. 75 Issue: 10 p2063-2072, 10p |
| Abstrakt: |
Although interleukin‐1 (IL‐1)/IL‐6 inhibitors are effective therapies for systemic juvenile idiopathic arthritis (JIA), some patients develop eosinophilia and lung disease during treatment. This study was undertaken to retrospectively evaluate incidence and risk factors for eosinophilia and describe lung disease outcomes in IL‐1/IL‐6 inhibitor–exposed patients with systemic JIA. Among JIA patients at our institution exposed to interleukin‐1 (IL‐1)/IL‐6 inhibitors (1995–2022), we compared incidence rate of eosinophilia in systemic JIA compared to other JIA, stratified by medication class (IL‐1/IL‐6 inhibitors, other cytokine inhibitors, methotrexate). We used Cox models to identify predictors of eosinophilia during IL‐1/IL‐6 inhibitor use and summarized treatment changes and outcomes after eosinophilia, including lung disease. HLA typing was performed on a clinical or research basis. There were 264 new medication exposures in 75 patients with systemic JIA and 41 patients with other JIA. A total of 49% of patients with systemic JIA with HLA typing (n = 45) were positive for HLA–DRB1*15 alleles. Eosinophilia was common during IL‐1/IL‐6 inhibitor use and did not differ by systemic JIA compared to other JIA (0.08 and 0.07 per person‐year, respectively; P= 0.30). Among systemic JIA patients, pretreatment macrophage activation syndrome (MAS) was associated with a higher rate of subsequent eosinophilia on biologic therapy (unadjusted hazard ratio 3.2 [95% confidence interval 1.2–8.3]). A total of 4 of 5 patients who switched therapy within 10 weeks of eosinophilia experienced disease flare compared to none of the patients who continued the original therapy. A total of 8 of 25 patients with pulmonary evaluations had lung disease, and all had severe manifestations of systemic JIA (MAS, intensive care unit stay). One death was attributed to systemic JIA–lung disease. Eosinophilia is common in JIA patients using IL‐1/IL‐6 inhibitors. Severe disease may be associated with eosinophilia and lung disease in systemic JIA. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text